Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready
Telix Pharmaceuticals (Innovations) Pty Ltd. is currently managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 4 pending office actions indicate the level of activity in the company's patent portfolio. The prosecution involves 3 distinct examiners, which means the company interacts with 3 different officials. With 3 distinct examiners, the portfolio's progress is distributed across different examination styles.
The company's applications are spread across 3 distinct art units. This distribution across 3 distinct art units reflects the technical range within the biotechnology and pharmaceutical sectors. MCDERMOTT, JEANNIE is the busiest examiner for this portfolio, currently overseeing 2 pending office actions. Since MCDERMOTT, JEANNIE is responsible for 2 pending office actions, this examiner has an impact on the portfolio's overall trajectory. The concentration of matters with a single individual requires attention to the specific preferences of the busiest examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCDERMOTT, JEANNIE | 2 | 59.8% | +15.7% |
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
| DAHLE, CHUN WU | 1 | 50.2% | +51.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18687806 | AGGREGATE SEPARATION METHOD | MCDERMOTT, JEANNIE | — |
| 18687283 | PREPARATORY PROCESS | MCDERMOTT, JEANNIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17622333 | ANTIBODIES FOR BINDING PSMA WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR | DAHLE, CHUN WU | 29d overdue |
| 18687806 | AGGREGATE SEPARATION METHOD | MCDERMOTT, JEANNIE | — |
| 18687283 | PREPARATORY PROCESS | MCDERMOTT, JEANNIE | — |
| 18547286 | Solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates and their use as precursors for therapeutic and/or diagnostic agents | DONOHUE, SEAN R | — |
| Art Unit | Apps |
|---|---|
| 1777 | 1 |
| 1618 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18687806 | AGGREGATE SEPARATION METHOD | MCDERMOTT, JEANNIE | 1777 | §102§103 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18687283 | PREPARATORY PROCESS | MCDERMOTT, JEANNIE | — | §102§103§112 | Non-Final OA | — | Pending | Feb 27, 2024 |
| 18547286 | Solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates and their use as precursors for therapeutic and/or diagnostic agents | DONOHUE, SEAN R | 1618 | §103 | Non-Final OA | — | Pending | Aug 21, 2023 |
| 17622333 | ANTIBODIES FOR BINDING PSMA WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR | DAHLE, CHUN WU | 1641 | §103 | Non-Final OA | 29d overdue | Pending | Dec 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial